ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O’Farrell to its Board of ...

If You Go What: Starship featuring Mickey Thomas & Foghat with Special Guests, Sic Vikki When: Saturday, July 12, at 6:30 p.m. Where: Spyglass Ridge Winery, 109 Carroll Road, Sunbury How much: $68.40 ...

BREMERTON — Jireh Soriano wanted to live in the place in Kitsap “where everything’s gonna be.” The Illahee resident would gladly shed his car for a walkable commute. He wants to live near the ...

Spyglass Ophthalmics是一家美国眼科治疗方案提供商，致力于开发用于治疗慢性眼科疾病的新型疗法。近日，Spyglass Ophthalmics获得7500万美元D轮融资，Sands Capital Ventures、Gilde Healthcare Partners、NEA恩颐投资-New Enterprise Associates、RA Capital ...

SpyGlass Pharma's drug delivery platform aims for long-term glaucoma management, delivering 3 years of bimatoprost to lower intraocular pressure. The $75 million Series D funding will support phase 3 ...

Financing supports SpyGlass Pharma’s platform through the readout of two Phase III pivotal trials ALISO VIEJO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic ...

[Image from the SpyGlass Pharma website] SpyGlass Pharma announced today that it closed a $75 million Series D financing round to support its drug delivery platform. Sands Capital led the financing ...

Spyglass (SPYG) today posted a big gain in revenues for its second quarter ended March 31, buoyed by a one-time payment from Microsoft for licensing rights to its Web browser technology. Shares of ...

First off, to anyone who followed me on Ludvig Åberg this week … an apology. I was banking on the young Swede being over his illness from Torrey Pines and I couldn’t have been more wrong. As painful ...

TORONTO & NEW YORK--(BUSINESS WIRE)--The Real Brokerage Inc. (NASDAQ: REAX), a technology platform reshaping real estate for agents, home buyers and sellers, today announced that Ryan Rodenbeck, one ...

SpyGlass Pharma has completed enrollment in its phase 1/2 clinical trial evaluating a long-term drug delivery platform of bimatoprost for glaucoma and ocular hypertension, according to a press release ...